NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
NOVAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novan, Inc. - (NOVN)

NEW ORLEANS, Nov. 17, 2017 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until January 2, 2018 to file lead plaintiff applications in a securities class action lawsuit against Novan, Inc. (Nasdaq: NOVN ), if they purchased the Company’s shares between September 26, 2016 and January 26, 2017 (the “Class Period”) and/or pursuant to its September 26, 2016 initial public offering (“IPO”).  This action is pending in the United States District Court for the Middle District of North Carolina.  

Get Help

Novan investors should visit us at https://www.claimsfiler.com/cases/view-novan-...litigation or call to speak to our claim center toll-free at (844) 367-9658.  

About the Lawsuit

Novan certain of its executives are charged with failing to disclose material information during the class period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company had initiated and conducted two identical Phase 3 clinical trials for its lead product candidate, SB204; (ii) in fact, the two SB204 Phase 3 clinical trials were not identical; and (iii) as a result of the foregoing, Novan’s financial statements were materially false and misleading at all relevant times.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading